Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yu N Linkova"'
Autor:
Yu. N. Linkova
Publikováno v:
Ведомости Научного центра экспертизы средств медицинского применения, Vol 13, Iss 4, Pp 488-492 (2023)
Clinical trials are the most important stage in the development of effective and safe medicinal products. Yu.N. Linkova, Candidate of Medical Sciences, Vice President for Clinical Research and Development at BIOCAD, shares her perspective on clinical
Externí odkaz:
https://doaj.org/article/075b4e3a558042b0afda1504e25e2c4b
Autor:
M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 11, Iss 2, Pp 215-230 (2023)
In recent years, there has been a significant increase in the number of patients with malignancies treated with immune checkpoint inhibitors (ICIs), including the anti-programmed cell death protein 1 (anti–PD-1) agent pembrolizumab. One of the impo
Externí odkaz:
https://doaj.org/article/37fb3277a00a434a919575561dd41b36
Autor:
V. I. Mazurov, A. M. Lila, M. A. Korolev, A. M. Prystrom, A. V. Kundzer, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Krechikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva, A. A. Lutckii, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 1, Pp 87-99 (2023)
Background. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here we present 1-y
Externí odkaz:
https://doaj.org/article/4769ca6bff3645e4857fcaa192e698f0
Autor:
N. V. Lomakin, B. A. Bakirov, G. H. Musaev, V. V. Popov, E. A. Smolyarchuk, Yu. N. Linkova, D. V. Bogdan, A. V. Eremeeva, P. S. Pukhtinskaia, M. A. Morozova, A. V. Zinkina-Orikhan, A. A. Lutckii
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 22, Iss 4, Pp 446-459 (2022)
The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti–IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19.The aim of the study was to assess the association of C
Externí odkaz:
https://doaj.org/article/ec0c3d78be484cc5aa9201db7e248aab
Autor:
D. V. Vlodavets, N. V. Ganina, E. S. Ilina, A. A. Kokorina, L. M. Kuzenkova, E. Yu. Sapego, D. S. Smirnov, Yu. A. Shevtsova, A. V. Saulina, A. N. Petrov, N. A. Zolkin, Yu. N. Linkova, A. V. Zinkina-Orikhan
Publikováno v:
Rossijskij Vestnik Perinatologii i Pediatrii, Vol 66, Iss 4, Pp 64-73 (2021)
Objective. To analyze the natural course of type 1 spinal muscular atrophy in children with the onset of the disease up to 6 months in the Russian population.Material and methods. The retrospective multicenter study included data of 54 children with
Externí odkaz:
https://doaj.org/article/f70391724f154e2ba1f5c21b766216e9
Autor:
V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii
Publikováno v:
Современная ревматология, Vol 15, Iss 4, Pp 13-23 (2021)
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in pati
Externí odkaz:
https://doaj.org/article/e5807cdebb9f4373ba05f16f3438579e
Autor:
V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 2, Pp 141-151 (2021)
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (
Externí odkaz:
https://doaj.org/article/b875e4d7b7464abf86d0680266117122
Autor:
A. I. Pavlov, S. M. Kirillov, D. S. Ponomarenko, A. K. Havanshanov, J. V. Fadina, I. V. Bobkova, V. I. Vasenko, G. A. Volodina, T. Yu. Kulikova, Yu. N. Linkova, M. A. Morozova
Publikováno v:
Журнал инфектологии, Vol 8, Iss 3, Pp 92-98 (2016)
The objective: to analyze the experience of use of cepeginterferonalfa-2b and ribavirin in patients with chronic hepatitis C genotypes 2 and 3 in clinical practice, to evaluate the efficacy, safety and tolerability of this treatment regimen.Materials
Externí odkaz:
https://doaj.org/article/b9463cfed95d4417bdbbb6be27dfc547
Publikováno v:
Терапевтический архив, Vol 88, Iss 11, Pp 156-162 (2016)
Since the incidence of chronic hepatitis C (CHC) increases steadily, the priority of national health care is to provide antiviral therapy (AVT) for the maximum number of patients infected with hepatitis C virus (HCV). The regimens including pegylated
Externí odkaz:
https://doaj.org/article/d1b8599975ac4f6a9e8ff4cb22342c04
Autor:
N. P. Blokhina, E. A. Nurmuhametova, M. G. Rusanova, I. V. Gagarina, E. S. Mar’jamova, N. A. Kuznetsova, T. V. Mar’janovskaja, T. V. Lopatina, O. V. Kuzina, I. N. Alekseeva, E. N. Shurenkova, A. V. Devjatkin, Yu. N. Linkova, M. A. Morozova
Publikováno v:
Журнал инфектологии, Vol 8, Iss 2, Pp 48-55 (2016)
The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical
Externí odkaz:
https://doaj.org/article/f89a71cd042c4a9f932d7e59b689efbe